CoChat
Sign Up
Cited by 261Prostate Cancer Treatment and ResearchCytokine Signaling Pathways and InteractionsProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index.

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Shariat, Shahrokh F., Andrews, Ben, Kattan, Michael W., Kim, JaHong, Wheeler, Thomas M., Slawin, Kevin M.·2001·Urology
DOI 10.1016/s0090-4295(01)01405-4
Open this paper in CoChat — free account

Abstract

Objectives Elevated circulating levels of interleukin 6 (IL-6) have been associated with cancer metastasis. IL-6 binds either to membrane or to soluble IL-6 receptor (IL-6sR), which then induces homodimerization of gp130 that activates downstream signaling. We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels are associated with prostate cancer stage, progression, and metastasis after radical prostatectomy.Methods Plasma levels of IL-6 and IL-6sR were measured in 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer, 44 healthy men without any cancer, 19 men with prostate cancer metastatic to the regional lymph nodes, and 10 men with prostate cancer metastatic to bone.Results Plasma IL-6 and IL-6sR levels were highest in patients with bone metastases (P <0.001). The preoperative IL-6 and IL-6sR levels were associated with the preoperative prostate-specific antigen (PSA) level (P </=0.041), prostatectomy tumor volume (P </=0.048), and final Gleason sum (P </=0.042). The preoperative IL-6 and IL-6sR levels and biopsy Gleason sum were independent predictors of PSA progression (P </=0.029). However, in a model that included both IL-6 and IL-6sR, only IL-6sR and the biopsy Gleason sum predicted progression (P </=0.040). In patients whose disease progressed, the preoperative IL-6 and IL-6sR levels were highest in those with presumed aggressive failure (P </=0.042).Conclusions Plasma IL-6 and IL-6sR levels were dramatically elevated in the men with prostate cancer metastatic to bone. In patients with clinically localized prostate cancer, the preoperative plasma IL-6 and IL-6sR levels independently predicted biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(01)01405-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 261

Related

See all

Metadata

Authors
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M.
Affiliations
  • Houston Methodist (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Slawin, Kevin M.
ORCID
Venue
Urology
Publisher
Elsevier BV
Published
2001-12
Volume
58
Issue
6
Pages
1008-1015
ISSN
0090-4295 (ISSN-L)
DOI
10.1016/s0090-4295(01)01405-4
OpenAlex
W2009017218
Cited by
261
References
35
Citations by year
2026: 6 · 2025: 1 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 17 · 2020: 5 · 2019: 5 · 2018: 10 · 2017: 9 · 2016: 9 · 2015: 19 · 2014: 10 · 2013: 12 · 2012: 8
FWCI
9.37
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Urology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1p20ca058203-01)
  • National Cancer Institute (CA58203)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
interleukin-6, soluble IL-6 receptor, prostate cancer, bone metastasis, biochemical recurrence, radical prostatectomy, prognostic factors, Gleason score, prostate-specific antigen, tumor progression, gp130 signaling
MeSH terms
Adult, Aged, Analysis of Variance, Biopsy, Bone Neoplasms, Follow-Up Studies, Humans, Male, Middle Aged, Prostate, Prostatectomy, Prostatic Neoplasms, Biomarkers, Tumor, Interleukin-6, Proportional Hazards Models, Disease Progression, Receptors, Interleukin-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review